Pioglitazone use and the risk of bladder cancer

Kaohsiung Journal of Medical Sciences

Mao-Meng Tiao¹  Hsin-Wei Kuo²  Chun-Yuh Yang³  Shu-Chen Ho⁴ 

[1] Department of Pediatrics, Kaohsiung Chang Gung Memorial Hospital and Chang Gung University College of Medicine, Kaohsiung, Taiwan;Division of Nephrology, Department of Internal Medicine, Yuan's General Hospital, Kaohsiung, Taiwan;Faculty of Public Health, College of Health Sciences, Kaohsiung Medical University, Kaohsiung, Taiwan;Institute of Occupational Safety and Health, College of Health Sciences, Kaohsiung Medical University, Kaohsiung, Taiwan;

关键词: Bladder cancer;    Diabetes;    Drug safety;    Pioglitazone;   

DOI  :  10.1016/j.kjms.2013.09.011

来源: DOAJ

【 摘 要 】

This study aimed to identify the risk association between pioglitazone exposure and bladder cancer. A nested case–control study was performed using a representative database randomly sampled from National Health Insurance enrollees. The source cohort consisted of newly diagnosed diabetic patients from 1997 to 2009. Cases were identified as those with a diagnosis of bladder cancer from 2002 to 2009. For each case, four matched control individuals were randomly selected. A multiple logistic regression model was used to estimate the relative magnitude of risk in relation to the use of pioglitazone. In total, 259 cases and 1036 controls were identified. The prevalent use of pioglitazone is similar in cases and controls (adjusted odds ratio, 1.20; 95% confidence interval, 0.58–2.49). Compared to nonusers, these values were 1.08 (0.41–2.88) for those with cumulative pioglitazone use ≤ 8268 mg and 1.35 (0.48–3.79) for those with cumulative pioglitazone use > 8268 mg. This study does not provide support for the risk association between pioglitazone exposure and bladder cancer. Further confirmation is needed due to the limitation of small case number with relatively shorter exposure duration and lower cumulative dose.

【 授权许可】

Unknown